Bausch + Lomb Releases Annual Environmental, Social and Governance Report

Report Highlights Progress and Priorities Across ESG Initiatives Around the World

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today released its annual Environmental, Social and Governance (ESG) Report, highlighting the Company’s ongoing commitment to implement sustainable business practices and initiatives that support its stakeholders’ well-being.

“Integrating environmental sustainability, social impact and corporate governance into our daily operations and business strategy has been a fundamental priority at Bausch + Lomb for many years,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “The dynamic and evolving nature of ESG presents several opportunities for improvement and growth, and we are proud to continue each year to build upon our ESG commitments, because we know this makes us a stronger company in ways that go beyond our mission of helping people see better to live better.”

The Bausch + Lomb 2022 ESG report highlights the Company’s continued efforts to drive sustainable growth, foster innovation and create value for all stakeholders. Key accomplishments highlighted in the 2022 ESG report include:

• Collecting more than 58 million units, or 356,000 pounds, of used contact lens, eye care and lens care materials through our ONE by ONE and Biotrue® Eye Care recycling programs since 2016;
• Reducing 800 tons of CO₂e (carbon dioxide emissions) per year at our Rochester facility since installing a solar panel array;
• Completing more than 8,500 hours of cybersecurity training by our employees;
• Exceeding the Company’s Board diversity goal of 30 percent with 40 percent board diversity;
• Achieving our corporate Not-to-Exceed-Days-Away-Rate (“DAR”) goal of 7.2 with a 5.6 DAR, which is a measure of the impact of workplace injuries and illnesses; and
• Piloting a six-month global mentorship program to increase mid-career development and to grow diversity, specifically among people of color and women in manager and director roles.

The full report can be viewed in the ESG section of Bausch + Lomb’s website here.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

© 2023 Bausch & Lomb Incorporated or its affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005114/en/